This brand name is authorized in Austria, Ecuador, Lithuania, Poland, Romania.
The drug LUIVAC contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
O478WX4004 - STAPHYLOCOCCUS AUREUS
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
2
|
UNII
P0PL12QNM1 - STREPTOCOCCUS MITIS
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
3
|
UNII
LJ2LP0YL98 - STREPTOCOCCUS PYOGENES
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
4
|
UNII
BT6U234YR2 - STREPTOCOCCUS PNEUMONIAE
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
5
|
UNII
09PA36CT5R - KLEBSIELLA PNEUMONIAE
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
6
|
UNII
1X259JGO78 - MORAXELLA CATARRHALIS
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
7
|
UNII
K738E2MB3I - HAEMOPHILUS INFLUENZAE
|
|
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L03AX | Other immunostimulants | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 28688-12-08 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1014180 |
| PL | Rejestru Produktów Leczniczych | 100099165, 100161154, 100244785 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W68395001, W68395002 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.